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Dear Sir, Following the publication of our article entitled "Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89 Zr-immunoPET" in EJNMMI [1] , readers sent us some remarks and questions. In this letter, we would like to address these questions by providing additional information about our study.
-DFOcyclo* is derived from DFO and not from DFO*.
In DFO*, the trihydroxamate DFO is elongated with an extra hydroxamate group, exactly the same as present in DFO. In DFOcyclo*, the DFO is elongated with a cyclic hydroxamate group having a different linker length. -During the manuscript review process, DFO*-NCS was made commercially available at ABX (catalogue number 7272). Therefore, the following statement in the introduction "However, in the absence of an improved, clinically applicable chelator, there is room for more efficient [ 89 Zr]Zr 4+ chelators" is no more correct. Fig. 4c . Once we observed an improved in vivo stability of [ 89 Zr]Zr-DFOcyclo*trastuzumab, a subsequent in vivo study was performed to investigate its stability compared with [ 8 9 Zr]Zr-DFO*-trastuzumab as well (Fig. 5) .
Although aimed at similar experimental conditions, the use of a freshly thawed cell line and new mice could have caused heterogeneity between the two experiments (e.g., increased tumor growth rates which result in different interstitial pressures that could affect the %ID/g), which could explain the slight differences in tumor uptake, blood kinetics, and uptake in other organs.
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